FrancophonIA/ELRC3.0 huggingface dataset:
English: Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare', and Granupas was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 December
Slovenian: Ker je bolnikov s tuberkulozo v EU malo, velja ta bolezen za redko, zato je bilo zdravilo Granupas 17. decembra 2010 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Previously known as Para-aminosalicylic acid Lucane
Slovenian: Predhodno znan kot para-aminosalicilna kislina Lucane
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Granupas's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Granupas večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
English: What benefits of Granupas have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Granupas izkazalo v študijah?
English: The applicant also provided published data on the doses of PAS to be used in children.
Slovenian: Predlagatelj je predložil tudi objavljene podatke o odmerkih para-aminosalicilne kisline za uporabo pri otrocih.
English: What are the risks associated with Granupas?
Slovenian: Kakšna tveganja so povezana z zdravilom Granupas?
English: For more information about treatment with Granupas, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Granupas preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What is Granupas and what is it used for?
Slovenian: Kaj je zdravilo Granupas in za kaj se uporablja?
English: The patients were treated for 3 months with either PAS or another medicine called streptomycin, or with a combination of PAS and streptomycin, and then followed up for 3 extra months.
Slovenian: Bolniki so tri mesece prejemali zdravljenje s para-aminosalicilno kislino ali drugim zdravilom, ki se imenuje streptomicin, ali kombinacijo para-aminosalicilne kisline in streptomicina, ter so jih nato spremljali še dodatne tri mesece.
English: In the second main study involving 341 patients aged over 12 years, PAS in combination with isoniazid was compared with isoniazid alone.
Slovenian: V drugi glavni študiji, v katero je bilo vključenih 341 bolnikov, starih več kot 12 let, so paraaminosalicilno kislino v kombinaciji z izoniazidom primerjali z izoniazidom v monoterapiji.
English: The recommended dose for adults is one sachet three times a day.
Slovenian: Priporočeni odmerek za odrasle je ena vrečka trikrat na dan. Zdravljenje običajno traja dve leti.
English: Multi-drug resistance is when the bacteria causing tuberculosis (Mycobacterium tuberculosis) are resistant to treatment with at least isoniazid and rifampicin, two standard tuberculosis medicines.
Slovenian: Odpornost proti več zdravilom pomeni, da so bakterije, ki povzročajo tuberkulozo (Mycobacterium tuberculosis), odporne najmanj na zdravljenje z izoniazidom in rifampicinom, tj. dvema standardnima zdraviloma proti tuberkulozi.
English: It is not intended to provide practical advice on how to use Granupas.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The full EPAR and risk management plan summary for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Granupas sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Why is Granupas approved?
Slovenian: Zakaj je bilo zdravilo Granupas odobreno?
English: For practical information about using Granupas, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Granupas naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Granupas, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For the full list of all side effects reported with Granupas, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Granupas, glejte navodilo za uporabo.
English: The benefits in combination with other tuberculosis treatments were shown in published studies presented by the company, two of which were considered to be the main studies for the application.
Slovenian: Koristi v kombinaciji z drugimi zdravili proti tuberkulozi so bile prikazane v objavljenih študijah, ki jih je družba predstavila.
English: It is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects.
Slovenian: Uporablja se v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, odporne proti več zdravilom, pri odraslih in otrocih, starejših od 28 dni, kadar zaradi odpornosti bolezni ali neželenih učinkov ni mogoče uporabiti drugih kombinacij brez tega zdravila.
English: The Committee noted that the active substance, PAS, has been shown to be beneficial when used in combination with other medicines to treat tuberculosis and that it helps reduce the emergence of resistance to other medicines.
Slovenian: Odbor je ugotovil, da se je zdravilna učinkovina, para-aminosalicilna kislina, izkazala kot koristna, kadar se uporablja v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, in da pomaga zmanjšati pojav odpornosti proti drugim zdravilom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Para-aminosalicylic acid Lucane on 7 April 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom , veljavno po vsej Evropski uniji, izdala 7. aprila 2014.
English: Granupas is a tuberculosis medicine that contains the active substance para-aminosalicylic acid (PAS).
Slovenian: Zdravilo Granupas je zdravilo za zdravljenje tuberkuloze, ki vsebuje zdravilno učinkovino paraaminosalicilna kislina (PAS).
English: PAS had been widely used in the past for combination treatment but was largely discontinued due to adverse effects on the stomach.
Slovenian: Para-aminosalicilno kislino so v preteklosti pogosto uporabljali za kombinirano zdravljenje, vendar so njeno uporabo precej zmanjšali zaradi neželenih učinkov na želodec.
English: The Committee also noted that the World Health Organization continues to recommend PAS as an option to be used in combination with other medicines for treating multi-drug resistant tuberculosis.
Slovenian: Odbor je prav tako ugotovil, da Svetovna zdravstvena organizacija še naprej priporoča paraaminosalicilno kislino kot možnost za uporabo v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, odporne proti več zdravilom.
English: PAS is similar to a chemical (para-aminobenzoic acid) that is used by the bacteria to make folic acid needed for new bacteria to grow.
Slovenian: Para-aminosalicilna kislina je podobna kemični snovi (paraaminobenzojski kislini), s pomočjo katere bakterija tvori folno kislino, ki je potrebna za rast novih bakterij.
English: It is available as 4 g sachets containing ‘gastroresistant' granules that allow the active substance to reach the intestine without being released in the stomach, thus reducing side effects in the stomach.
Slovenian: Na voljo je v 4-gramskih vrečkah, ki vsebujejo „gastrorezistentna zrnca“, zasnovana tako, da zdravilna učinkovina doseže črevesje, ne da bi se sprostila v želodcu, s čimer se zmanjšajo neželeni učinki v želodcu.
English: The CHMP noted that Granupas contains gastro-resistant granules, designed to allow PAS to reach the intestine without being released in the stomach, and thus reduce the potential for side effects.
Slovenian: CHMP je ugotovil, da zdravilo Granupas vsebuje gastrorezistentna zrnca, ki so zasnovana tako, da lahko para-aminosalicilna kislina doseže črevesje, ne da bi se sprostila v želodcu, s tem pa se zmanjša možnost neželenih učinkov.
English: para-aminosalicylic acid
Slovenian: Granupas para-aminosalicilna kislina
English: After 12 months, 90% of patients in the combination group did not have the bacteria in their phlegm compared with 51% of patients given a comparable dose of isoniazid alone.
Slovenian: Po 12 mesecih bakterije v sluzi ni imelo 90 % bolnikov v skupini, ki je prejemala kombinirano zdravljenje, v primerjavi z 51 % bolnikov, ki so prejemali primerljiv odmerek samega izoniazida.
English: The active substance, PAS, is a ‘bacteriostatic agent', which means that it works by stopping the growth of M. tuberculosis bacteria.
Slovenian: Zdravilna učinkovina, para-aminosalicilna kislina, je bakteriostatik, kar pomeni, da deluje tako, da zaustavi rast bakterije M. tuberculosis.
English: By interfering and taking the place of this chemical in the processes that make folic acid, para-aminosalicylic acid reduces the amount of folic acid produced and thereby stops or slows the growth of M. tuberculosis.
Slovenian: Para-aminosalicilna kislina v procesih tvorbe folne kisline vpliva na to kemično snov in jo nadomesti, s tem pa zmanjša količino nastale folne kisline in zaustavi ali upočasni rast bakterije M. tuberculosis.
English: PAS in combination with streptomycin also helped reduce the emergence of resistance to streptomycin: in 89% of patients receiving the combination the bacteria remained responsive to streptomycin, compared with 21% of patients who were given only streptomycin.
Slovenian: Para-aminosalicilna kislina je v kombinaciji s streptomicinom pomagala zmanjšati tudi pojav odpornosti proti streptomicinu: bakterija je postala odzivna na streptomicin pri 89 % bolnikov, ki so prejemali kombinirano zdravljenje, v primerjavi z 21 % bolnikov, ki so prejemali samo streptomicin.
English: In addition, the PAS-isoniazid combination helped reduce the emergence of resistance to isoniazid: after 1 year, while 47% of patients in the isoniazid-only group had resistant bacteria the figure was only 8% in the combination group.
Slovenian: Poleg tega je kombinacija para-aminosalicilne kisline in izoniazida pomagala zmanjšati pojav odpornosti proti izoniazidu: po enem letu je v skupini, ki je prejemala samo izoniazid, odpornost proti bakteriji razvilo 47 % bolnikov, v skupini, ki je prejemala kombinirano zdravljenje, pa samo 8 %.
English: How does Granupas work?
Slovenian: Kako zdravilo Granupas deluje?
English: At the end of the 6 months, 87% of patients on the combination had improvements in their chest x-rays compared with 56% of patients in the group taking PAS alone.
Slovenian: Po šestih mesecih so pri rentgenskem slikanju prsnega koša zabeležili izboljšanje pri 87 % bolnikov, ki so prejemali kombinirano zdravljenje, v primerjavi s 56 % bolnikov v skupini, ki je prejemala samo para-aminosalicilno kislino.
English: How is Granupas used?
Slovenian: Kako se zdravilo Granupas uporablja?
English: Granupas can only be obtained with a prescription.
Slovenian: Izdaja zdravila je le na recept.
English: In addition,33% of patients in the combination group had no bacteria detected in their phlegm (sputum) compared with 8% in the PAS group.
Slovenian: Poleg tega bakterije v sluzi (izpljunku) niso zaznali pri 33 % bolnikov v skupini, ki je prejemala kombinirano zdravljenje, v primerjavi z 8 % bolnikov v skupini, ki je prejemala para-aminosalicilno kislino.
English: This overview was last updated in 06-2019
Slovenian: Povzetek je bil nazadnje posodobljen 06-2019.
English: Further information on Miglustat Gen.Orph can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/miglustat-genorph.
Slovenian: Nadaljnje informacije za zdravilo Miglustat Gen.Orph so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/miglustat-genorph.
English: • adults (aged 18 years and above) with mild to moderate type-1 Gaucher disease.
Slovenian: • odraslih (starejših od 18 let) z blago do zmerno obliko Gaucherjeve bolezni tipa 1.
English: Miglustat Gen.Orph received a marketing authorisation valid throughout the EU on 10 November 2017.
Slovenian: Za zdravilo Miglustat Gen.Orph je bilo 10. novembra 2017 izdano dovoljenje za promet, veljavno po vsej EU.
English: • patients of all ages with Niemann-Pick type-C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body.
Slovenian: • bolnikov vseh starosti z Niemann-Pickovo boleznijo tipa C, ki je lahko smrtna in pri kateri se glikosfingolipidi kopičijo v celicah v možganih in drugod v telesu.
English: Because Miglustat Gen.Orph is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Miglustat Gen.Orph generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Miglustat Gen.Orph has been shown to have comparable quality and to be bioequivalent to Zavesca.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Miglustat Gen.Orph primerljivo raven kakovosti kot referenčno zdravilo Zavesca ter da mu je bioekvivalentno.
English: Studies on the benefits and risks of the active substance in Gaucher disease have already been carried out with the reference medicine, Zavesca, and do not need to be repeated for Miglustat Gen.Orph.
Slovenian: Študije o koristih in tveganjih učinkovine pri Gaucherjevi bolezni so že bile izvedene z referenčnim zdravilom Zavesca, zato jih ni treba ponoviti za zdravilo Miglustat Gen.Orph.
English: Miglustat Gen.Orph is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves).
Slovenian: Zdravilo Miglustat Gen.Orph se uporablja za zdravljenje nevroloških simptomov bolezni (simptomov, ki prizadenejo možgane in živce).
English: For more information about using Miglustat Gen.Orph, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij o uporabi zdravila Miglustat Gen.Orph glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Side effects reported with Miglustat Gen.Orph are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Miglustat Gen.Orph, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Miglustat Gen.Orph is used in patients who cannot receive the standard treatment of enzymereplacement therapy (ERT);
Slovenian: Zdravilo Miglustat Gen.Orph se uporablja pri bolnikih, ki ne morejo prejemati običajnega encimskega nadomestnega zdravljenja (ERT);
English: What measures are being taken to ensure the safe and effective use of Miglustat Gen.Orph?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Miglustat Gen.Orph?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Miglustat Gen.Orph have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Miglustat Gen.Orph upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Miglustat Gen.Orph is a ‘generic medicine'.
Slovenian: Miglustat Gen.Orph je „generično zdravilo“.
English: For Niemann-Pick type-C disease, it is two capsules three times a day for patients aged 12 years and over; in younger patients, the dose depends on their weight and height.
Slovenian: Priporočeni začetni odmerek za Gaucherjevo bolezen tipa 1 je ena kapsula trikrat na dan. Priporočeni začetni odmerek za Niemann-Pickovo bolezen tipa C sta dve kapsuli trikrat na dan za bolnike, starejše od 12 let; odmerek pri mlajših bolnikih je odvisen od njihove telesne mase in višine.
English: Miglustat Gen.Orph is used to treat the following patients:
Slovenian: Zdravilo Miglustat Gen.Orph se uporablja za zdravljenje naslednjih bolnikov:
English: As for every medicine, the company provided studies on the quality of Miglustat Gen.Orph.
Slovenian: Kot to velja za vsako zdravilo, je podjetje zagotovilo študije o kakovosti zdravila Miglustat Gen.Orph.
English: An overview of Miglustat Gen.Orph and why it is authorised in the EU
Slovenian: Pregled zdravila Miglustat Gen.Orph in zakaj je odobreno v EU
English: What are the benefits and risks of Miglustat Gen.Orph?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Miglustat Gen.Orph?
English: As for all medicines, data on the use of Miglustat Gen.Orph are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Miglustat Gen.Orph stalno spremljajo.
English: What is Miglustat Gen.Orph and what is it used for?
Slovenian: Kaj je zdravilo Miglustat Gen.Orph in za kaj se uporablja?
English: The medicine can only be obtained with a prescription and treatment should be supervised by doctors who are experienced in the management of Gaucher disease.
Slovenian: Predpisovanje in izdaja zdravila Miglustat Gen.Orph je le na recept, zdravljenje z njim pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z Gaucherjevo boleznijo.
English: The active substance in Miglustat Gen.Orph, miglustat, blocks an enzyme called glucosylceramide synthase.
Slovenian: Učinkovina zdravila Miglustat Gen.Orph, miglustat, preprečuje delovanje encima, imenovanega glukozilceramidsintaza.
English: This means that Miglustat Gen.Orph contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Zavesca.
Slovenian: To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Zavesca.
English: Why is Miglustat Gen.Orph authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Miglustat Gen.Orph odobreno v EU?
English: Other information about Miglustat Gen.Orph
Slovenian: Druge informacije o zdravilu Miglustat Gen.Orph
English: Miglustat Gen.Orph is available as 100 mg capsules to be taken by mouth.
Slovenian: Zdravilo Miglustat Gen.Orph je na voljo v obliki 100-miligramskih kapsul, ki se jemljejo peroralno.
English: Miglustat Gen.Orph is used to treat two inherited diseases that affect the way the body handles fats.
Slovenian: Zdravilo Miglustat Gen.Orph se uporablja za zdravljenje dveh dednih bolezni, ki vplivata na način presnove maščob v telesu.
English: Miglustat Gen.Orph is intended for long-term use.
Slovenian: Zdravilo Miglustat Gen.Orph je namenjeno za dolgotrajno uporabo.
English: Therefore, the Agency's view was that, as for Zavesca, the benefit of Miglustat Gen.Orph outweighs the identified risk and it can be authorised for use in the EU.
Slovenian: Zato je menila, da koristi zdravila Miglustat Gen.Orph enako kot pri zdravilu Zavesca odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
English: How has Miglustat Gen.Orph been studied?
Slovenian: Kako je bilo zdravilo Miglustat Gen.Orph raziskano?
English: How does Miglustat Gen.Orph work?
Slovenian: Kako zdravilo Miglustat Gen.Orph deluje?
English: How is Miglustat Gen.Orph used?
Slovenian: Kako se zdravilo Miglustat Gen.Orph uporablja?
English: Date of first authorisation: 19 July 2006 Date of latest renewal: 21 July 2011
Slovenian: Datum prve odobritve: 19. julij 2006 Datum zadnjega podaljšanja: 21. julij 2011
English: Risk management plan (RMP)
Slovenian: • Načrt za obvladovanje tveganja (RMP)
English: These can usually be treated by your doctor.
Slovenian: Običajno jih lahko zdravi vaš zdravnik.
English: - If you have high blood pressure.
Slovenian: - če imate visok krvni tlak.
English: The nominal alpha value for this analysis was 0.0094.
Slovenian: Nominalna alfa vrednost te analize je bila 0,0094.
English: The absolute bioavailability is not known.
Slovenian: Absolutna biološka uporabnost ni znana.
English: - If you are taking Neomycin or other antibiotics.
Slovenian: - če jemljete neomicin ali druge antibiotike.
English: 20024 Garbagnate Milanese Italy
Slovenian: 20024 Garbagnate Milanese Italija
English: Dose reductions were only partially successful in alleviating adverse reactions.
Slovenian: Zmanjšanja odmerkov so bila le delno uspešna pri lajšanju neželenih učinkov.
English: Doxorubicin/Irinotecan
Slovenian: Doksorubicin/irinotekan
English: The tablets should be swallowed with a glass of water.
Slovenian: Tablete je treba zaužiti z vodo (kozarec vode).
English: Effects of other antibiotics have not been studied, but will likely depend on their ability to interfere with microorganisms with glucuronidase activity.
Slovenian: Učinkov ostalih antibiotikov niso preučevali, vendar so najverjetneje odvisni od njihovega delovanja na mikroorganizme z glukuronidazno aktivnostjo.
English: Laboratory parameter, (in % of samples investigated)
Slovenian: Laboratorijski kazalec (v % preučevanih vzorcev)
English: Such events are either uncommon or less frequent than uncommon.
Slovenian: Ti dogodki se pojavljajo občasno ali celo manj pogosto kot občasno.
English: - If you have a heart disorder, such as an abnormal electrical signal called "prolongation of the QT interval".
Slovenian: - če imate motnje v delovanju srca, kot npr. nenormalen električni signal imenovan »podaljšanje intervala QT«.
English: This booklet was last revised in {month YYYY}.
Slovenian: Navodilo je bilo nazadnje revidirano dne {mesec LLLL}
English: Tell your doctor if any of these affect you.
Slovenian: Obvestite zdravnika, če kar koli od naštetega velja tudi za vas.
English: Analyses of demographic data suggest that there is no relationship between pharmacokinetics and age (up to 65 years), gender or body weight.
Slovenian: Analize demografskih podatkov kažejo, da ni povezave med farmakokinetiko in bolnikovo starostjo (do 65 let), spolom ali telesno maso.
English: Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), not known (cannot be estimated from the available data).
Slovenian: Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: In this case your doctor will interrupt the treatment.
Slovenian: V takem primeru bo zdravnik zdravljenje prenehal.
English: Disease specific warnings
Slovenian: Za bolezen specifična opozorila
English: The study was stopped after a planned interim analysis of OS had crossed the prespecified efficacy boundary.
Slovenian: Študija je bila ustavljena po načrtovani vmesni analizi celokupnega preživetja, ker je bila presežena vnaprej določena meja učinkovitosti.
English: It is important to take this medicine at about the same times each day, so that there is a steady amount in the bloodstream.
Slovenian: Pomembno je, da to zdravilo jemljete vsak dan ob približno istem času, saj se tako vzdržuje stalna vrednost zdravila v krvnem obtoku.
English: The elimination half-life of sorafenib is approximately 25 - 48 hours.
Slovenian: Razpolovna doba izločanja sorafeniba je približno 25 do 48 ur.
English: Gastrointestinal perforation
Slovenian: Gastrointestinalna perforacija